(NASDAQ:PRAN) is trading down by 6.15% at $3.21 and is one of the laggers in today’s market. More than 25 shares have changed hands.
Short traders are feeling a little more bullish of late at least if you consider the decrease in short interest. The company saw a fall in short interest of -8.14% as of the latest report on October 13, 2017. Short interest fell from 80,796 to 74,221 over that period. The days to cover decreased to 6.0 and the percentage of shorted shares was 0.00% on October 13.
A few notable investment firms have updated their holdings. Citadel Advisors LLC expanded its position by buying 1,933 shares an increase of 16.0% from 06/30/2017 to 09/30/2017. Citadel Advisors LLC owns 14,002 shares valued at $39,000. The value of the position overall is up by 39.3%. Bank Of America Corp /de/ trimmed its ownership by selling 691 shares a decrease of 74.1%. Bank Of America Corp /de/ now holds 242 shares with a value of $1,000. The total value of its holdings decreased 50.0%.
As of the end of the quarter Ubs Group Ag had bought 3,591 shares growing its position 950.0%. The value in dollars went from $1,000 to $11,000 a change of $10,000 quarter over quarter.
The P/E ratio is N/A and the market cap is 28.10M. In the last earnings report the EPS was $-3.85 with 88.98M shares presently outstanding.
Prana Biotechnology Limited, launched on November 11, 1997, is a development-stage medical biotechnology company. The Company is involved in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Business’s lead product candidates are PBT2 and PBT434. The Business’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders. PBT2 is a small molecule that reversibly binds and transports copper and zinc within neurons and across synapses..